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On April 21st, JSPH sponsored an event at the 
National Press Club in Washington, DC entitled: 
“Regulation of Follow-on Biologics: Ensuring Quality 
and Patient Safety.” Supported by an unrestricted 
educational grant from sanofi-aventis, the event 
brought together a wide range of experts in 
the medical field including doctors, scientists, 
economists and others who discussed the quality 
and safety issues surrounding the creation of a 
regulatory pathway to bring follow-on biologic drugs 
to market in the United States.  
Featured speakers included: Michael McCaughan, 
Editor in Chief of the Pink Sheet; Ann Witt, JD, Health 
Counsel to Rep. Henry A. Waxman; Brian Harvey, 
MD, PhD, VP, Regulatory Policy, sanofi-aventis; Terry 
Hisey, Vice Chairman, U.S. Life Sciences Leader, 
Deloitte LLP; and Geno Merli, MD, FACP, FHM, Chief 
Medical Officer, Thomas Jefferson University Hospital 
and Director, Jefferson Center for Vascular Diseases at 
Jefferson Medical College.
Research and development costs for biologics 
are very high and, as a result, therapy with these 
agents for patients with chronic diseases is very 
expensive.  Because these products are derived by 
modifying living organisms, the end product is 
especially sensitive to damage or contamination, 
and small differences in the manufacturing 
process may have unforeseen and unintended 
effects on therapeutic action. 
There is a movement to spur the development of 
“follow-on” biologics (FOBs) similar to the original 
products in an effort to improve access and lower 
overall costs to the health care system. Congress is 
intent on passing legislation enabling the Food and 
Drug Administration (FDA) to develop a regulatory 
pathway for FOBs similar to the pathway for generic 
forms of traditional drugs.  Well crafted legislation for 
FOBs will afford an opportunity to reduce drug costs 
and make better quality healthcare more affordable  
for millions of American families.
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Currently, there are competing bills under 
consideration in the House; one authored by Rep. 
Henry A. Waxman (D-Calif.), Chairman of the 
House Energy and Commerce Committee, and the 
other drafted by Rep. Anna Eshoo (D-Calif.).  In the 
Senate, Charles Schumer (D-NY) has introduced a 
companion to the Waxman proposal. 
At the conference, there was broad support for greater 
accessibility of FOBs.  However, significant concerns 
were expressed for patient-safety, “interchangeability” 
problems and product testing issues that must be 
thoroughly addressed.
Some key themes on patient safety which emerged 
from the event are as follows:
1.   Patient safety must be the number one priority, 
including adequate safety testing prior to the 
approval of any FOB. 
2.   The US should adopt some of the more successful 
and proven provisions of European regulation, such 
as its clarity around the circumstances and extent of 
testing required of FOBs. 
3.   An FOB approval pathway must be comprehensive 
and recognize the complex nature of all biologic 
medications, including proteins and polysaccharides.
4.   Biologic efficacy is not the same as biologic 
effectiveness.  FOBs must be evaluated for patient 
outcomes.
The outcome of this debate is likely to have far-
reaching implications with regard to access, cost, safety, 
and therapeutic impact for thousands of patients with 
serious, life-threatening, and chronic diseases.     
The conference webcast has been archived and can be 
accessed online at:   
www.visualwebcaster.com/FOB-Policy-Forum.
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